Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12111262 | 0.93 | FKBP5 (0.36) | UHRF1NNMT | |
| SCHEMBL3993569 | 0.85 | — | — | |
| SCHEMBL31712915 | 0.80 | — | — | |
| SCHEMBL5761227 | 0.74 | UHRF1 (0.34) | UHRF1NNMT | |
| SCHEMBL5758641 | 0.74 | UHRF1 (0.34) | UHRF1NNMT | |
| SCHEMBL13355387 | 0.73 | UHRF1 (0.53) | UHRF1NNMT | |
| SCHEMBL31712943 | 0.70 | CHEK1 (0.37) | — | |
| SCHEMBL30375761 | 0.70 | — | — | |
| SCHEMBL13444 | 0.70 | NPC1 (0.36) | — | |
| SCHEMBL1313095 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | claimed |
| US-7101869-B2 | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | claimed |
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | BLUMENKOPF TODD A (US) | 2003-10-09 | — | — | US | claimed |
| EP-1242403-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001040215-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-11807634-B2 | Cyclopropyl dihydroquinoline sulfonamide compounds | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807634-B2 | Cyclopropyl dihydroquinoline sulfonamide compounds | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116981458-A | Compounds with tetrahydroindole-1-carboxamides as BCL-2 inhibitors | 伊尔治疗学股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230234948-A1 | CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230227442-A1 | HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227442-A1 | HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2023088441-A1 | KIF18A INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7101869-B2 | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | BLUMENKOPF TODD A (US) | 2003-10-09 | — | — | US | disclosed |
| EP-1242403-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040215-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | CCR1, AOC1, NOD1 | UHRF1 2946/4885NNMT 1670/4885OR51E2 1887/4885 |
| US-20070123510-A1 | Guanidine derivatives | NPFFR1, NPFFR2, OGFR | UHRF1 1516/4885NNMT 264/4885OR51E2 2827/4885 |
| US-20230227442-A1 | HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | SCN7A, TRPV1, SCNN1A | UHRF1 4665/4885NNMT 2784/4885OR51E2 1516/4885 |
| US-20230234948-A1 | CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS | TRPV1, SCN7A, TRPA1 | UHRF1 4825/4885NNMT 1628/4885OR51E2 1715/4885 |
| US-11807634-B2 | Cyclopropyl dihydroquinoline sulfonamide compounds | TRPV1, SCN7A, TRPA1 | UHRF1 4825/4885NNMT 1561/4885OR51E2 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.